“…In our cohort, there were 19 premature neonates (o 36 weeks), the youngest being 23 weeks gestational age, weighing 530 grams, who was treated without an increased occurrence of bleeding or supra-therapeutic levels compared to term neonates. One of 40 patients (2.5%) in our cohort attained a supratherapeutic anti-Xa level after the loading phase, whereas Bauman et al 10 reported o 1% (5/514) risk of achieving supratherapeutic anti-Xa levels during the same phase. However, it is difficult to compare the two study populations.…”